Provided by Tiger Trade Technology Pte. Ltd.

Oric Pharmaceuticals Inc.

14.01
-0.1950-1.37%
Volume:553.91K
Turnover:7.65M
Market Cap:1.45B
PE:-10.36
High:14.52
Open:14.16
Low:13.56
Close:14.20
52wk High:14.93
52wk Low:7.23
Shares:103.52M
Float Shares:88.69M
Volume Ratio:0.67
T/O Rate:0.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3513
EPS(LYR):-1.4747
ROE:-39.80%
ROA:-25.97%
PB:3.80
PE(LYR):-9.50

Loading ...

Oric Pharmaceuticals should be bought on selloff, says Citi

TIPRANKS
·
Apr 02

Oric Pharmaceuticals price target lowered to $17 from $20 at Wedbush

TIPRANKS
·
Apr 01

Wall Street Set to Open Higher as Trump Says US Will Consider Ceasefire if Hormuz Strait Opened

MT Newswires Live
·
Apr 01

Oric Pharmaceuticals Is Maintained at Outperform by Wedbush

Dow Jones
·
Apr 01

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (DMAC), Elevance Health (ELV) and Oric Pharmaceuticals (ORIC)

TIPRANKS
·
Apr 01

Oric Pharmaceuticals (ORIC) Receives a Buy from Evercore ISI

TIPRANKS
·
Apr 01

Top Premarket Decliners

MT Newswires Live
·
Apr 01

Guggenheim Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)

TIPRANKS
·
Apr 01

Wedbush Cuts Price Target on ORIC Pharmaceuticals to $17 From $20, Keeps Outperform Rating

MT Newswires Live
·
Apr 01

Oric Pharmaceuticals Shares Fall on Side Effect Data in Prostate Cancer Drug Trial

Dow Jones
·
Apr 01

ORIC Pharmaceuticals Stock Nosedives 25% After Hours: What Is Going On?

Benzinga_recent_news
·
Apr 01

Oric Advances Rinzimetostat Toward First Prostate Cancer Phase 3

TIPRANKS
·
Apr 01

24H|DEFT Soared 50%; NCino Surged 20%; Oric Pharmaceuticals Plunged 25%; Battalion Oil Down 9%

Tiger Newspress
·
Apr 01

Oric Pharmaceuticals announces rinzimetostat, ORIC-944, program update

TIPRANKS
·
Apr 01

ORIC Pharmaceuticals to Launch Phase 3 Trial of Prostate Cancer Drug Candidate, Shares Falter

MT Newswires Live
·
Apr 01

Oric Pharmaceuticals: Continue to Evaluate Rinzimetostat in Additional Indications in Prostate Cancer and Beyond

THOMSON REUTERS
·
Apr 01

Oric Pharmaceuticals: Expect First Phase 3 Trial, Himalayas-1, in Patients With Mcrpc Previously Treated With Abiraterone, to Initiate in H1 2026

THOMSON REUTERS
·
Apr 01

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

GlobeNewswire
·
Apr 01

Oric Pharmaceuticals to present Phase 1b rinzimetostat combination dose-optimization data in mCRPC; March 31 conference call set for 4:30pm ET

Reuters
·
Mar 27

Oric® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1B Trial of Rinzimetostat in Patients With Mcrpc

THOMSON REUTERS
·
Mar 27